Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia

American Journal of Hematology

Volumn 90, Issue 6, 2015, Pages 561-563

  Sehl, Mary E ^a   Gruber, Theresa M ^a   Mcwilliams, Justin P ^a   Marder, Victor J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BEVACIZUMAB; HEMOGLOBIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHRONIC KIDNEY DISEASE; CRYOPRECIPITATE; EPISTAXIS; FAMILY HISTORY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; MALE; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; BLOOD; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84929514418     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23969     Document Type: Article

References (23)

1. Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-924.
2. Lupu A, Stefanescu C, Treton X, et al. Bevacizumab as rescue treatment for severe recurrent GI bleeding in HHT. J Clin Gastroenterol 2013;47:256-257.
3. Fodstad P, Dheyauldeen S, Rinde M, Bachmann-Harildstad G. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011;90:611-612.
4. Chen S IV, Karnezis T, Davidson TM. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011;121:644-646.
5. Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2012;269:531-536.
6. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;360:2143-2144.
7. Lacout A, Marcy PY, El Hajjam M, Lacombe P. Transexamic acid-bevacizumab synergy in HHT patients presenting with pulmonary AVMs. Med Hypotheses 2012;79:605-606.
8. Kanellopoulou T, Alexopoulou A. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther 2013;13:1315-1323.
9. Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009;119:988-992.
10. Dheyauldeen S, Østertun Geirdal A, Osnes T, et al. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: Effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope 2011;122:1210-1214.
11. Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 2012;122:495-497.
12. Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transplant 2013;14:210-213.
13. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with HHT and severe hepatic vascular malformations and high cardiac output. JAMA 2012;307:948-955.
14. Lacout A, Marcy PY, El Hajjam M, Lacombe P. Transexamic acid and bevacizumab in hereditary hemorrhagic telangiectasia patients presenting with epistaxis. Cutis 2013;91:173-174.
15. Chavan A, Schumann-Binarsch S, Luthe L, et al. Systemic therapy with bevacizumab in patients with HHT. Vasa 2013;42:106-110.
16. Vlachou PA., Colak E, Koculym A, et al. Improvement of ischemic cholangiopathy in 3 patients with HTT following treatement with bevacizumab. J Hepatol 2013;59:186-189.
17. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85:631-632.
18. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-β1 as well as high ALK1 tissue expression. Haematologica 2005;90:818-828.
19. Walker EJ, Su H, Shen F, et al. Arteriovenous malformation in the adult mouse brain resembling the human disease. Ann Neurol 2011;69:954-962.
20. Walker EJ, Su H, Shen F, et al. Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke 2012;43:1925-1930.
21. Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010;16:420-428.
22. Danyel LA, Schmerler P, Paulis L, et al. Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure. Integr Blood Press Control 2013;6:153-161.
23. Geirdal AØ, Dheyauldeen S, Bachmann-Harildstad G, Heimdal K. Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: A population based study. Am J Med Genet A 2012;158A:1269-1278.